Journal of Research and Development
A Multidisciplinary International Level Referred and Double Blind Peer Reviewed, Open Access
ISSN : 2230-9578 | Website: https://jrdrvb.org Volume-17, Issue-12| December 2025

Original Article

# The Antibiotic Resistance Crisis: A Review of Emerging Antimicrobial Agents

**Kanchan Mala[1], Prof (Dr.) Vikas Verma[2]**
[1]Research Scholar, Department of Chemistry, Faculty of Science, P.K. University, Shivpuri (M.P.)
[2] Department of Chemistry, Faculty of Science, P.K. University, Shivpuri (M.P.)
**Email:** kanchanmala85@gmail.com

**Manuscript ID**:
JRD -2025-171207
ISSN: 2230-9578
Volume 17
Issue 12
Pp. 37-43
December 2025

***Abstract***

*The global antibiotic resistance crisis has become a serious risk to public health, marked by the quick rise of multidrug-resistant bacterial strains. This review explores the discovery and development of novel antimicrobial agents aimed at combating resistant bacterial infections. Focusing on synthetic and natural antimicrobial compounds, the review highlights promising agents such as Zosurabalpin, Cresomycin, and Eravacycline, which have shown efficacy against resistant pathogens like Carbapenem-resistant Acinetobacter baumannii (Crab) and Methicillin-resistant Staphylococcus aureus (MRSA). M mechanisms of resistance, including multidrug efflux pumps and enzymatic degradation,are discussed to understand the challenges of addressing antimicrobial resistance (AMR). Emphasis is placed on innovative strategies, including molecular targeting and biotechnology-driven solutions, to mitigate the crisis. The assessment emphasizes how urgently further research and international cooperation are needed to develop effective antimicrobial therapies and policies to counteract this growing threat to modern medicine.*

***Keywords:*** *Antibiotic resistance crisis, Emerging antimicrobial agents, Multidrug-resistant bacteria, Synthetic and natural antibiotics, Antimicrobial resistance mechanisms.*

**Submitted:** 15 Nov. 2025
**Revised:** 25 Nov. 2025
**Accepted:** 10 Dec. 2025
**Published:** 31 Dec. 2025

## Introduction

One urgent global health concern that jeopardizes the effectiveness of contemporary therapy is antimicrobial resistance (AMR). The rapid emergence of resistant pathogens has rendered many conventional antibiotics ineffective, leading to an increased burden of untreatable infections. This challenge poses significant risks to public health, with greater incidence of morbidity and death, as well as economic strain on healthcare systems.AMR is caused by a number of variables, such as the overuse and abuse of antibiotics in agriculture and healthcare, as well as the spread of resistance genes through social and environmental pathways. To tackle this increasing problem, the intricacy of AMR calls for creative solutions, such as the creation of new antimicrobial compounds and the adoption of sustainable methods.

## 1 Overview of Antimicrobial Resistance (AMR)

AMR occurs when bacteria, viruses, and fungi change to avoid the consequences of antimicrobial agents, rendering them ineffective. This resistance undermines the treatment of infections, making even routine medical procedures potentially life-threatening [1]. The widespread frequency of pathogens resistant to many drugs, including carbapenem-resistant Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus (MRSA), highlights the need for urgent action to counteract the AMR crisis [2].Environmental factors, including The problem is made worse by the propagation of resistant genes through the food chain, soil, and water. In these environments, organic pollutants play a part in fostering the selection and survival of resistance microbes in addition to human abuse of antibiotics.[3]. Addressing these interconnected drivers is critical to mitigating AMR on a global scale.



**Address for correspondence:**
*Kanchan Mala, Research Scholar, Department of Chemistry, Faculty of Science, P.K. University, Shivpuri (M.P.)*

**How to cite this article:**
*Mala, K., & Verma, V. (2025). The Antibiotic Resistance Crisis: A Review of Emerging Antimicrobial Agents. Journal of Research and Development, 17(12), 37–43. https://doi.org/10.5281/zenodo.18068035*

Quick Response Code:
Website: https://jrdrvb.org/
DOI: 10.5281/zenodo.18068035
OPEN ACCESS

Journal of Research and Development
A Multidisciplinary International Level Referred and Double Blind Peer Reviewed, Open Access
ISSN : 2230-9578 | Website: https://jrdrvb.org Volume-17, Issue-12| December 2025

**2 Importance of Discovering New Antimicrobial Agents**

Developing new antimicrobial agents is essential to counter the limitations of current therapies in combating resistant bacterial strains. Novel agents with innovative mechanisms of action, such as Zosurabalpin and Cresomycin, have shown promise in overcoming resistance barriers and addressing critical threats posed by multidrug-resistant pathogens [4]. These advancements are particularly vital as resistance mechanisms, including enzymatic degradation and efflux pumps, continue to challenge the efficacy of traditional antibiotics.Emerging therapeutic strategies, such as photodynamic therapy and biotechnological innovations, provide a foundation for the next generation of antimicrobial agents. These approaches aim to minimize the development of resistance while enhancing the effectiveness of treatment. Collaborative research and investment in antimicrobial development are crucial to ensuring a sustainable response to the AMR crisis, safeguarding public health, and preserving The developments in contemporary medicine [5].

**The Current State of Antimicrobial Agents**

One of the most urgent issues nowadays is the quick emergence of antibiotic resistance in modern medicine. Despite the success of antimicrobial agents in treating infections, their effectiveness has been compromised by the evolving resistance mechanisms of microorganisms. This section explores the current state of antimicrobial agents, including their types, mechanisms of action, historical development, and the limitations that have emerged over time. Understanding these factors is essential for dealing with the escalating resistance threat..

**1 Types and Mechanisms of Action**

Antimicrobial Agents are categorized according to how they work, which include targeting bacterial cell walls, protein synthesis, DNA replication, or metabolic pathways. For example, β-lactam antibiotics like penicillins inhibit cell wall synthesis, while aminoglycosides target protein synthesis. Antifungal agents disrupt fungal cell membranes or inhibit key metabolic enzymes, whereas antivirals block viral replication processes [6]. These agents have played a critical role in combating infectious diseases by exploiting vulnerabilities unique to microorganisms.

However, the efficacy of these agents varies, and resistance has emerged against nearly all classes of antibiotics. For instance, *Klebsiella pneumoniae* Treatment options are limited since high-risk clones like ST307 and ST147 have become resistant to carbapenems [9]. To overcome these obstacles, a greater comprehension of microbial processes and the evolution of innovative therapeutics to counteract resistance.

**2 Historical Development and Limitations**

The discovery of antibiotics, starting with penicillin in 1928, revolutionized medication and considerably lowered infectious illness death rates. But overuse and abuse of these medications have sped up the development of resistant strains over time. Newer agents, while effective initially, often lose their efficacy due to adaptive microbial mechanisms [10].




**Figure 1: number of Drugs Approved**

The pharmaceutical pipeline for antibiotics has slowed, with limited economic incentives for companies to invest in antimicrobial research. This stagnation has left healthcare systems vulnerable to multidrug-resistant organisms. Innovative approaches, such as non-essential target inhibitors and alternative therapies, are being explored to fill the gap left by traditional antibiotics [13].

**Antimicrobial Resistance: The Crisis**

**1 Mechanisms of Resistance Development**

The enzymatic breakdown of antibiotics, alteration of drug targets, and efflux pumps that remove medicines from the cell are some of the ways that microorganisms acquire resistance. Resistance genes can spread quickly across bacterial populations thanks to horizontal gene transfer, further compounding the problem [8].

Journal of Research and Development
A Multidisciplinary International Level Referred and Double Blind Peer Reviewed, Open Access
ISSN : 2230-9578 | Website: https://jrdrvb.org Volume-17, Issue-12| December 2025

The development of resistance is also significantly influenced by environmental variables, such as the existence of antimicrobial pollutants in soil and water. The persistence and spread of resistance in both clinical and non-clinical contexts are facilitated by these pollutants' selection for resistant strains [6]. Addressing these mechanisms requires a comprehensive approach that integrates environmental, medical, and regulatory strategies.




**Figure 2: Mechanism of Antiviotic Resistance**

### 2 Impact on Public Health and Medicine

AMR has profound implications for global public health, affecting the treatment of infections and increasing the risk of surgical complications. Diseases once considered manageable, such as MRSA infections, are now becoming more difficult to cure, resulting in longer hospital stays and higher medical expenses [10]. AMR was made worse by the COVID-19 pandemic because of the extensive use of antibiotics in managing secondary bacterial infections [7].
Food safety and quality are also impacted by AMR, as resistant bacteria enter the food chain through agricultural practices. This underscores the need for stringent antimicrobial stewardship in both human medicine and agriculture to mitigate the crisis [12]. Without immediate action, the AMR crisis could undermine decades of progress in modern medicine.

### Literature Review

| **Theme** | **Authors** | **Key Findings** | **Gaps Identified** |
|---|---|---|---|
| **Emerging AMR Trends** | (Flynn et al., 2023) | The study highlights the evolving nature of antimicrobial resistance (AMR), particularly emerging resistant strains. | The environmental factors influencing resistance are not thoroughly examined. |
| **Global AMR Overview** | (Tang et al., 2023) | Comprehensive overview of AMR, its global prevalence, and contributing factors. | Limited regional studies on AMR spread in rural areas. |
| **Photodynamic Therapy** | (Mathur et al., 2023) | Photodynamic therapy is emerging as a novel treatment for ESKAPE pathogens resistant to common antibiotics. | The long-term efficacy of photodynamic therapy is yet to be fully explored. |
| **AMR in Food Chain** | (EFSA Panel et al., 2021) | Environmental contamination through the food chain contributes significantly to the spread of AMR. | The impact of agricultural practices on AMR transmission remains underexplored. |
| **Emerging Contaminants and AMR** | (Alderton et al., 2021) | AMR develops as a result of emerging organic pollutants, especially in environmental situations. | There is insufficient data on how these contaminants interact with microbial ecosystems. |

| | | | |
|---|---|---|---|
| **AMR and COVID-19** | (Ghosh et al., 2021) | AMR risks have significantly increased during the COVID-19 pandemic, complicating public health responses. | Few studies have addressed the intersection of AMR and COVID-19 management strategies. |
| **Klebsiella pneumoniae Clones** | (Peirano et al., 2020) | High-risk Klebsiella pneumoniae clones ST307 and ST147 are emerging as major global threats due to their antimicrobial resistance. | Surveillance of these clones in non-hospital environments is limited. |
| **AMR in Food Safety** | (Nelson et al., 2019) | AMR poses significant challenges to food quality and safety, especially in the context of global food supply chains. | There is a need for more comprehensive global monitoring systems. |
| **Non-Essential Target Inhibitors** | (Annunziato, 2019) | Non-essential target inhibitors show potential in overcoming AMR, providing a new avenue for antimicrobial drug development. | The clinical applicability of these inhibitors needs further validation. |
| **EFSA's Role in AMR** | (Stella et al.,2018) | EFSA plays a crucial role in mitigating AMR through policy formulation and risk assessment in the food industry. | More collaborative efforts between public health and agricultural sectors are needed. |
| **Global AMR Crisis** | (Aslam et al., 2018) | AMR is a global crisis, with multidrug-resistant organisms becoming increasingly difficult to treat. | Research on the socio-economic impacts of AMR remains sparse. |
| **AMR Surveillance in ICUs** | (Moolchandani et al., 2017) | AMR monitoring is essential in intensive care units, especially in high-risk hospital settings. | The variability of AMR patterns in different ICU settings needs further study. |
| **Global AMR Threat** | (Ferri et al., 2017) | AMR poses a growing risk to public health worldwide, and immediate action is required to international policy interventions. | The role of socioeconomic factors in AMR development remains under-investigated. |
| **AMR in Military Healthcare** | (Khan et al., 2017) | Military healthcare settings are particularly vulnerable to emerging AMR, which may also have wider societal implications. | More research on AMR in non-hospitalized military settings is needed. |
| **Listeria monocytogenes and AMR** | (Allen et al., 2016) | Listeria monocytogenes and its role in foodborne AMR transmission were studied, with implications for food safety protocols. | The specific interactions between Listeria strains and resistant bacteria require further exploration. |

Journal of Research and Development
A Multidisciplinary International Level Referred and Double Blind Peer Reviewed, Open Access
ISSN : 2230-9578 | Website: https://jrdrvb.org Volume-17, Issue-12| December 2025

| | | | |
|---|---|---|---|
| **AMR in Saudi Arabia** | (Zowawi, 2016) | Saudi Arabia faces a significant AMR challenge, with urgent calls for action to prevent further resistance spread. | There is a lack of comprehensive national surveillance programs for AMR. |
| **AMR in Canada** | (Ebrahim et al., 2016) | AMR trends in Canada show significant resistance, especially to commonly used antibiotics. | Better regional tracking and antibiotic stewardship programs are needed. |
| **Global AMR Problem** | (Yadav and Prakas, 2016) | AMR is a critical global health problem, exacerbated by overuse and misuse of antibiotics. | More international collaborations are necessary to address AMR in low-income countries. |
| **AMR as a Global Phenomenon** | (Prestinaci et al., 2015) | AMR is a multifaceted problem requiring coordinated action across sectors. | The role of international trade and tourism in spreading AMR remains inadequately studied. |
| **Ethical Implications of AMR** | (Littmann and Viens, 2015) | Ethical implications of AMR have been under-explored, particularly concerning healthcare access and equity. | More ethical frameworks need to be developed for AMR management. |
| **AMR as a Disaster** | (Viens and Littmann, 2015) | AMR poses a slowly emerging disaster with significant ethical and public health concerns. | Immediate policy interventions are needed to prevent further escalation. |
| **AMR Control in Asia** | (Song, 2015) | AMR control measures in Asia are varied, and more consistent strategies are needed to combat this rising threat. | Regional differences in AMR control strategies should be further examined. |

## Innovations in Antimicrobial Agents

### 1 Emerging Synthetic Compounds

Synthetic antimicrobial compounds have been designed to combat resistant bacterial strains by targeting their unique vulnerabilities. These include molecules engineered to bypass bacterial resistance mechanisms, such as efflux pumps and enzymatic degradation. Novel β-lactam derivatives and cyclic peptides, for instance, have shown promise in treating multidrug-resistant pathogens. Additionally, advanced methods like photodynamic therapy utilize light-activated compounds to kill resistant bacteria, offering a new dimension in antimicrobial therapy.

These synthetic agents are developed with enhanced stability, specificity, and reduced toxicity, making them effective alternatives to traditional antibiotics. Their application also extends to targeting infections associated with biofilm formation, a common challenge in antibiotic therapy.

### 2 Natural Product-Based Antimicrobials

Natural products continue to serve as a cornerstone in antimicrobial discovery. Compounds like teixobactin and omadacycline, derived from microbial metabolites, exhibit potent activity against resistant bacteria. These agents operate through mechanisms distinct from synthetic drugs, which makes them less prone to resistance development.

Plant-based antimicrobials, such as phytochemicals, also offer promising solutions. Substances like flavonoids and terpenoids combat bacterial infections by disrupting membranes and inhibiting critical enzymatic pathways. These natural compounds are considered eco-friendly and sustainable, complementing synthetic antimicrobial development.

### 3 Notable Case Studies (e.g., Zosurabalpin, Eravacycline)

Zosurabalpin and Eravacycline stand out as significant advancements in combating resistant bacterial strains. Zosurabalpin targets by rupturing the cell membranes of gram-negative bacteria, such as Acinetobacter baumannii,

which is resistant to carbapenem. A synthetic tetracycline derivative called eravacycline works well against vancomycin-resistant Enterococci (VRE) and Methicillin-resistant Staphylococcus aureus (MRSA).
These agents exemplify the potential of combining innovative chemistry with targeted therapeutic approaches, addressing both bacterial infections that are both Gram-positive and Gram-negative.

**Challenges and Opportunities**

**1 Overcoming Resistance Mechanisms**

Developing new antimicrobial agents involves addressing bacterial resistance mechanisms such as enzymatic degradation, efflux pumps, and biofilm formation. Strategies like combination therapies, which pair antibiotics with resistance inhibitors, have proven effective in mitigating these challenges. Additionally, advancements in genomics and proteomics have provided deeper insights into the molecular pathways of resistance, aiding in the design of targeted and effective antimicrobial therapies. However, continuous evolution of resistance requires persistent innovation in research and development.

**2 Role of Biotechnology and Drug Design**

Biotechnology is transforming antimicrobial development by enabling high-throughput screening and precision drug design. Tools like CRISPR-based approaches and artificial intelligence allow researchers to identify novel targets and optimize drug efficacy.Drug delivery systems, such as nanoparticles and liposomes, enhance the bioavailability and stability of antimicrobial agents, ensuring targeted action against infections. These technological advancements are critical for addressing the limitations of traditional antibiotics and creating next-generation treatments.

**Future Directions**

**1 Promising Research Areas**

Future research should prioritize alternative therapeutic approaches, including phage therapy, antimicrobial peptides, and quorum-sensing inhibitors. These methods offer non-traditional pathways to combat bacterial infections and reduce the reliance on conventional antibiotics. The role of the human microbiome in influencing antimicrobial resistance also presents a promising research avenue. Understanding these dynamics can help develop strategies to manage resistance at the microbial community level.

**2 Policy and Global Collaboration**

Addressing antimicrobial resistance requires strong policy frameworks and global collaboration. Effective antimicrobial stewardship programs, aimed at minimizing misuse in both healthcare and agriculture, are essential. Governments and organizations must also incentivize pharmaceutical companies to invest in antimicrobial research.
International initiatives that promote data sharing and collaboration, such as global surveillance systems, can enhance the collective understanding of resistance trends. Public-private partnerships and sustained funding are vital to fostering innovation and ensuring equitable access to new therapies worldwide.

**Conclusion**

The overuse of antibiotics and the rise of multidrug-resistant bacteria are the main causes of the antibiotic resistance issue, which is a serious danger to world health , and environmental factors. Promising advancements, such as novel agents like Zosurabalpin and Eravacycline, offer hope, but challenges persist due to the complexity of resistance mechanisms and gaps in research and surveillance. To combat this crisis, it is essential to promote global collaboration, invest in alternative therapies, implement strict antimicrobial stewardship programs, and reduce environmental dissemination of resistance. Strengthening policy frameworks and incentivizing innovation are crucial to preserving the effectiveness of antimicrobial treatments.

**References**

1. Flynn, C. E., & Guarner, J. (2023). Emerging antimicrobial resistance. *Modern Pathology*, *36*(9), 100249.
2. Tang, K. W. K., Millar, B. C., & Moore, J. E. (2023). Antimicrobial resistance (AMR). *British Journal of Biomedical Science*, *80*, 11387.
3. Mathur, A., Parihar, A. S., Modi, S., & Kalra, A. (2023). Photodynamic therapy for ESKAPE pathogens: An emerging approach to combat antimicrobial resistance (AMR). *Microbial pathogenesis*, 106307.
4. Chang, R. Y. K., Nang, S. C., Chan, H. K., & Li, J. (2022). Novel antimicrobial agents for combating antibiotic-resistant bacteria. *Advanced drug delivery reviews*, *187*, 114378.
5. EFSA Panel on Biological Hazards (BIOHAZ), Koutsoumanis, K., Allende, A., Álvarez‐Ordóñez, A., Bolton, D., Bover‐Cid, S., ... & Peixe, L. (2021). Role played by the environment in the emergence and spread of antimicrobial resistance (AMR) through the food chain. *Efsa Journal*, *19*(6), e06651.
6. Alderton, I., Palmer, B. R., Heinemann, J. A., Pattis, I., Weaver, L., Gutiérrez-Ginés, M. J., ... & Tremblay, L. A. (2021). The role of emerging organic contaminants in the development of antimicrobial resistance. *Emerging Contaminants*, *7*, 160-171.
7. Ghosh, S., Bornman, C., & Zafer, M. M. (2021). Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?. *Journal of infection and public health*, *14*(5), 555-560.

8. Moo, C. L., Yang, S. K., Yusoff, K., Ajat, M., Thomas, W., Abushelaibi, A., ... & Lai, K. S. (2020). Mechanisms of antimicrobial resistance (AMR) and alternative approaches to overcome AMR. *Current drug discovery technologies*, *17*(4), 430-447.
9. Peirano, G., Chen, L., Kreiswirth, B. N., & Pitout, J. D. (2020). Emerging antimicrobial-resistant high-risk Klebsiella pneumoniae clones ST307 and ST147. *Antimicrobial agents and chemotherapy*, *64*(10), 10-1128.
10. Watkins, R. R., Holubar, M., & David, M. Z. (2019). Antimicrobial resistance in methicillin-resistant Staphylococcus aureus to newer antimicrobial agents. *Antimicrobial agents and chemotherapy*, *63*(12), 10-1128.
11. Thombre, R., Jangid, K., Shukla, R., & Dutta, N. K. (2019). Alternative therapeutics against antimicrobial-resistant pathogens. *Frontiers in microbiology*, *10*, 2173.
12. Nelson, D. W., Moore, J. E., & Rao, J. R. (2019). Antimicrobial resistance (AMR): significance to food quality and safety. *Food quality and safety*, *3*(1), 15-22.
13. Annunziato, G. (2019). Strategies to overcome antimicrobial resistance (AMR) making use of non-essential target inhibitors: A review. *International journal of molecular sciences*, *20*(23), 5844.
14. Stella, P., Beloeil, P. A., Guerra, B., Hugas, M., & Liebana, E. (2018). The Role of the European Food Safety Authority (EFSA) in the Fight against Antimicrobial Resistance (AMR). *Food Protection Trends*, *38*(1).
15. Williamson, D. A., Lane, C. R., Easton, M., Valcanis, M., Strachan, J., Veitch, M. G., ... & Howden, B. P. (2018). Increasing antimicrobial resistance in nontyphoidal Salmonella isolates in Australia from 1979 to 2015. *Antimicrobial Agents and Chemotherapy*, *62*(2), 10-1128.
16. Aslam, B., Wang, W., Arshad, M. I., Khurshid, M., Muzammil, S., Rasool, M. H., ... & Baloch, Z. (2018). Antibiotic resistance: a rundown of a global crisis. *Infection and drug resistance*, 1645-1658.
17. Jansen, K. U., & Anderson, A. S. (2018). The role of vaccines in fighting antimicrobial resistance (AMR). *Human vaccines & immunotherapeutics*, *14*(9), 2142-2149.
18. Sharma, C., Rokana, N., Chandra, M., Singh, B. P., Gulhane, R. D., Gill, J. P. S., ... & Panwar, H. (2018). Antimicrobial resistance: its surveillance, impact, and alternative management strategies in dairy animals. *Frontiers in veterinary science*, *4*, 237.
19. Moolchandani, K., Sastry, A. S., Deepashree, R., Sistla, S., Harish, B. N., & Mandal, J. (2017). Antimicrobial resistance surveillance among intensive care units of a tertiary care hospital in Southern India. *Journal of clinical and diagnostic research: JCDR*, *11*(2), DC01.
20. Ferri, M., Ranucci, E., Romagnoli, P., & Giaccone, V. (2017). Antimicrobial resistance: A global emerging threat to public health systems. *Critical reviews in food science and nutrition*, *57*(13), 2857-2876.
21. Khan, I. D., Gupta, R. M., Sen, S., Rajmohan, K. S., Jindal, A. K., Makkar, A., ... & Singh, S. (2017). Emerging antimicrobial resistance and evolving healthcare: Dangerous crossroads for the community and the military. *Journal of Archives in Military Medicine*, *5*(3).
22. Ayukekbong, J. A., Ntemgwa, M., & Atabe, A. N. (2017). The threat of antimicrobial resistance in developing countries: causes and control strategies. *Antimicrobial Resistance & Infection Control*, *6*, 1-8.
23. Brinkac, L., Voorhies, A., Gomez, A., & Nelson, K. E. (2017). The threat of antimicrobial resistance on the human microbiome. *Microbial ecology*, *74*(4), 1001-1008.
24. Marston, H. D., Dixon, D. M., Knisely, J. M., Palmore, T. N., & Fauci, A. S. (2016). Antimicrobial resistance. *Jama*, *316*(11), 1193-1204.
25. Ryu, S. (2017). The new Korean action plan for containment of antimicrobial resistance. *Journal of global antimicrobial resistance*, *8*, 70-73.
26. Allen, K. J., Wałecka-Zacharska, E., Chen, J. C., Katarzyna, K. P., Devlieghere, F., Van Meervenne, E., ... & Bania, J. (2016). Listeria monocytogenes–An examination of food chain factors potentially contributing to antimicrobial resistance. *Food Microbiology*, *54*, 178-189.
27. Zowawi, H. M. (2016). Antimicrobial resistance in Saudi Arabia: An urgent call for an immediate action. *Saudi medical journal*, *37*(9), 935.
28. Ebrahim, M., Gravel, D., Thabet, C., Abdesselam, K., Paramalingam, S., & Hyson, C. (2016). Anitmicrobial Resistance (AMR): Antimicrobial use and antimicrobial resistance trends in Canada: 2014. *Canada Communicable Disease Report*, *42*(11), 227.
29. Yadav, K., & Prakas, S. (2016). Antimicrobial Resistance (AMR): a global problem. *Glob J Pub Health Epidemiol*, *3*(1), 120-138.
30. Prestinaci, F., Pezzotti, P., & Pantosti, A. (2015). Antimicrobial resistance: a global multifaceted phenomenon. *Pathogens and global health*, *109*(7), 309-318.
31. Littmann, J., & Viens, A. M. (2015). The ethical significance of antimicrobial resistance. *Public health ethics*, *8*(3), 209-224.
32. Viens, A. M., & Littmann, J. (2015). Is antimicrobial resistance a slowly emerging disaster?. *Public health ethics*, *8*(3), 255-265.
33. Song, J. (2015). Antimicrobial resistance control in Asia. *AMR control*, 41-45.